Tags

Type your tag names separated by a space and hit enter

Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
Contraception. 1994 Jan; 49(1):33-46.C

Abstract

A comparative study of two low-dose oral contraceptives, gestodene (GES) 75 mcg/ethinyl oestradiol (EE) 30 mcg and desogestrel (DES) 150 mcg/EE 20 mcg, was conducted in women over 30 years of age. This randomised, open-label study was organised in Denmark, Italy, New Zealand and United Kingdom. A total of 505 women received GES/EE and 501 received DES/EE for 6 consecutive menstrual cycles. The two groups were comparable in terms of demographic and gynaecologic characteristics at baseline. However, the menstrual flow length was slightly longer in the GES/EE group before the start of the treatment. The mean age (+/- SD) was 35 +/- 4 years in the GES/EE group and 35 +/- 5 years in the DES/EE group. The subjects in the GES/EE group contributed data for a total of 2800 cycles and those in the DES/EE group, data for 2796 cycles. There were no pregnancies on medication with either preparation. The results showed that there were significantly more normal cycles in the GES/EE group for cycles 1 to 6. Irregular bleeding between withdrawal bleeds occurred in 10% of GES/EE and 18.5% of DES/EE cycles. Absence of all bleeding was reported in 29 (1%) and 63 (2%) cycles, respectively. The incidence of missed pills was low in both groups (11% of cycles). No significant differences were observed in cycle length or withdrawal bleeding episode length. Withdrawal bleeding mean intensity was statistically significantly greater with GES/EE. However, for both preparations, the mean intensity was close to light bleeding. No clinically significant differences were noted in weight, blood pressure, Papanicolaou smears or laboratory data. Sixty-eight (13.5%) subjects in the GES/EE group and 64 (12.8%) in the DES/EE group discontinued before the end of the study. Among them, 37 (7%) and 40 (8%) in the respective groups withdrew because of adverse reactions. There was no difference between groups in terms of primary reasons for withdrawal. The most frequently reported complaints that led to discontinuation in both groups were headache, nausea and metrorrhagia. Breast tenderness led to the discontinuation of 1 subject in the GES/EE group and 3 in the DES/EE group. These results show excellent cycle control, efficacy and very low rate of side effects with both GES/EE and DES/EE. These low-dose oral contraceptives could be well suited to healthy nonsmoking women requiring contraception up to the age of menopause.

Authors+Show Affiliations

University of Manchester, Palatine Centre, England.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8137624

Citation

Kirkman, R J., et al. "Clinical Comparison of Two Low-dose Oral Contraceptives, Minulet and Mercilon, in Women Over 30 Years of Age." Contraception, vol. 49, no. 1, 1994, pp. 33-46.
Kirkman RJ, Pedersen JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994;49(1):33-46.
Kirkman, R. J., Pedersen, J. H., Fioretti, P., & Roberts, H. E. (1994). Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception, 49(1), 33-46.
Kirkman RJ, et al. Clinical Comparison of Two Low-dose Oral Contraceptives, Minulet and Mercilon, in Women Over 30 Years of Age. Contraception. 1994;49(1):33-46. PubMed PMID: 8137624.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. AU - Kirkman,R J, AU - Pedersen,J H, AU - Fioretti,P, AU - Roberts,H E, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez KW - Age Factors--women KW - Clinical Research KW - Clinical Trials KW - Comparative Studies KW - Contraception KW - Contraception Continuation KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Effectiveness KW - Contraceptive Methods--side effects KW - Contraceptive Usage KW - Demographic Factors KW - Denmark KW - Desogestrel KW - Developed Countries KW - Diseases KW - Europe KW - Family Planning KW - Gestodene KW - Italy KW - Mediterranean Countries KW - Menstrual Cycle KW - Menstruation KW - Menstruation Disorders KW - New Zealand KW - Northern Europe KW - Oceania KW - Oral Contraceptives, Low-dose--side effects KW - Oral Contraceptives--side effects KW - Population KW - Population Characteristics KW - Reproduction KW - Research Report KW - Scandinavia KW - Southern Europe KW - Studies KW - United Kingdom SP - 33 EP - 46 JF - Contraception JO - Contraception VL - 49 IS - 1 N2 - A comparative study of two low-dose oral contraceptives, gestodene (GES) 75 mcg/ethinyl oestradiol (EE) 30 mcg and desogestrel (DES) 150 mcg/EE 20 mcg, was conducted in women over 30 years of age. This randomised, open-label study was organised in Denmark, Italy, New Zealand and United Kingdom. A total of 505 women received GES/EE and 501 received DES/EE for 6 consecutive menstrual cycles. The two groups were comparable in terms of demographic and gynaecologic characteristics at baseline. However, the menstrual flow length was slightly longer in the GES/EE group before the start of the treatment. The mean age (+/- SD) was 35 +/- 4 years in the GES/EE group and 35 +/- 5 years in the DES/EE group. The subjects in the GES/EE group contributed data for a total of 2800 cycles and those in the DES/EE group, data for 2796 cycles. There were no pregnancies on medication with either preparation. The results showed that there were significantly more normal cycles in the GES/EE group for cycles 1 to 6. Irregular bleeding between withdrawal bleeds occurred in 10% of GES/EE and 18.5% of DES/EE cycles. Absence of all bleeding was reported in 29 (1%) and 63 (2%) cycles, respectively. The incidence of missed pills was low in both groups (11% of cycles). No significant differences were observed in cycle length or withdrawal bleeding episode length. Withdrawal bleeding mean intensity was statistically significantly greater with GES/EE. However, for both preparations, the mean intensity was close to light bleeding. No clinically significant differences were noted in weight, blood pressure, Papanicolaou smears or laboratory data. Sixty-eight (13.5%) subjects in the GES/EE group and 64 (12.8%) in the DES/EE group discontinued before the end of the study. Among them, 37 (7%) and 40 (8%) in the respective groups withdrew because of adverse reactions. There was no difference between groups in terms of primary reasons for withdrawal. The most frequently reported complaints that led to discontinuation in both groups were headache, nausea and metrorrhagia. Breast tenderness led to the discontinuation of 1 subject in the GES/EE group and 3 in the DES/EE group. These results show excellent cycle control, efficacy and very low rate of side effects with both GES/EE and DES/EE. These low-dose oral contraceptives could be well suited to healthy nonsmoking women requiring contraception up to the age of menopause. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/8137624/Clinical_comparison_of_two_low_dose_oral_contraceptives_Minulet_and_Mercilon_in_women_over_30_years_of_age_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(94)90107-4 DB - PRIME DP - Unbound Medicine ER -